Edarbyclor (Takeda Pharmaceuticals America, Inc.)
Welcome to the PulseAid listing for the Edarbyclor drug offered from Takeda Pharmaceuticals America, Inc.. This Angiotensin 2 Type 1 Receptor Antagonists [MoA],Angiotensin 2 Receptor Blocker [EPC],Decreased Blood Pressure [PE],Increased Diuresis [PE],Thiazide-like Diuretic [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Takeda Pharmaceuticals America, Inc. |
| NON-PROPRIETARY NAME: | azilsartan medoxomil and chlorthalidone |
| SUBSTANCE NAME: | AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Angiotensin 2 Type 1 Receptor Antagonists [MoA],Angiotensin 2 Receptor Blocker [EPC],Decreased Blood Pressure [PE],Increased Diuresis [PE],Thiazide-like Diuretic [EPC] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2011-12-23 |
| END MARKETING DATE: | 2018-05-01 |
Edarbyclor HUMAN PRESCRIPTION DRUG Details:
| Item Description | Edarbyclor from Takeda Pharmaceuticals America, Inc. |
| LABELER NAME: | Takeda Pharmaceuticals America, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 40; 12.5(mg/1; mg/1) |
| START MARKETING DATE: | 2011-12-23 |
| END MARKETING DATE: | 2018-05-01 |
| PRODUCT ID: | 64764-944_90260686-0297-4334-b577-5cdb3f0a3129 |
| PRODUCT NDC: | 64764-944 |
| APPLICATION NUMBER: | NDA202331 |
Other AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE Pharmaceutical Manufacturers / Labelers:
